Modelling costs of dementia in Australia: Evidence, gaps, and needs

Australian Health Review

Volumn 32, Issue 3, 2008, Pages 479-487

  Nepal, Binod ^a   Ranmuthugala, Geetha ^a   Brown, Laurie ^a   Budge, Marc ^b,c  

^a UNIVERSITY OF CANBERRA   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; AUSTRALIA; COST OF ILLNESS; ECONOMICS; HEALTH CARE COST; HEALTH SERVICES RESEARCH; HUMAN; PREVALENCE; RISK FACTOR; STATISTICS;

ALZHEIMER DISEASE; AUSTRALIA; COST OF ILLNESS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH SERVICES RESEARCH; HUMANS; PREVALENCE; RISK FACTORS;

EID: 56849103607     PISSN: 01565788     EISSN: 14498944     Source Type: Journal    
DOI: 10.1071/AH080479     Document Type: Article

References (29)

1. Wimo A, Winblad B, Jönsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement 2007; 3: 81-91.
2. Brown L, Thurecht L, Yap M, et al. Economic modelling of the prevention of type 2 diabetes in Australia. Final report. Canberra: National Centre for Social and Economic Modelling, University of Canberra, 2006.
3. Access Economics. The dementia epidemics: economic impact and positive solutions for Australia. Canberra: Access Economics (for Alzheimer's Australia), 2003.
4. Australian Institute of Health and Welfare. Dementia in Australia: national data analysis and development. Canberra: AIHW, 2007. (AIHW Cat. No. AGE 53).
5. Mathers C, Stevenson C, Carter R, et al. Disease costing methodology used in the disease costs and impact study 1993-94. Canberra: Australian Institute of Health and Welfare, 1998. (AIHW Cat. No. HWE 7).
6. Access Economics. Dementia estimates and projections: Australian states and territories. Canberra: Access Economics (for Alzheimer's Australia), 2005.
7. Australian Bureau of Statistics. Population projections, Australia, 2004 to 2101. Canberra: ABS, 2005. (ABS Cat. No. 3222.0).
8. Woodward M. Dementia: can it be prevented? Alzheimer's Australia, 2005. (Position Paper No. 6).
9. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-42.
10. Jorm AF, Dear KB, Burgess NM. Projections of future numbers of dementia cases in Australia with and without prevention. Aust N Z J Psychiatry 2005; 39: 959-63.
11. McNamee P, Bond J, Buck D. Costs of dementia in England and Wales in the 21st century. Br J Psychiatry 2001; 179: 261-6.
12. Access Economics. Delaying the onset of Alzheimer's disease: projections and issues. Canberra: Access Economics (for Alzheimer's Australia), 2004.
13. Brookmeyer R, Johnson E, Ziegler K, et al. Forecasting the global burden of Alzheimer's disease. Baltimore: Department of Biostastics, Johns Hopkins Bloomberg School of Public Health, 2007. (Paper 130.)
14. Ostbye T, Crosse E. Net economic costs of dementia in Canada. CMAJ 1994; 151: 1457-64.
15. Wimo A, Karlsson G, Sandman PO, et al. Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997; 12: 857-61.
16. Hux MJ, O'Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 1998; 159: 457-65.
17. Leon J, Neumann PJ. The cost of Alzheimer's disease in managed care: a cross-sectional study. Am J Manag Care 1999; 5: 867-77.
18. Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, et al. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 2006; 67: 2186-91.
19. Jonsson L, Eriksdotter Jonhagen M, Kilander L, et al. Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 449-59.
20. Australian Health Ministers' Conference. National framework for action on dementia. Sydney: New South Wales Department of Health on behalf of AHMC, 2006.
21. Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006; 5: 735-41.
22. Wimo A, Winblad B. Economic aspects on drug therapy of dementia. Curr Pharm Des 2004; 10: 295-301.
23. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004; 47: 1747-59.
24. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003; 26: 3093-101.
25. Mui SL. Projecting coronary heart disease incidence and cost in Australia: results from the incidence module of the Cardiovascular Disease Policy Model. Aust N Z J Public Health 1999; 23: 11-19.
26. Jones AP, Homer JB, Murphy DL, et al. Understanding diabetes population dynamics through simulation modeling and experimentation. Am J Public Health 2006; 96: 488-94.
27. University of Oxford Diabetes Trials Unit. UKPDS outcomes model user manual (version 1.1). Oxford: University of Oxford, 2005.
28. Eddy DM, Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care 2003; 26: 3102-10.
29. Bloom LA, Bloom BS. Decision analytic modeling in health care decision making. Oversimplifying a complex world? Int J Technol Assess Health Care 1999; 15: 332-9.